Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile

Simple item page
dc.article.number6836
dc.catalogadorjlo
dc.contributor.authorJara Vallejos, Alejandro Antonio
dc.contributor.authorCuadrado, Cristóbal
dc.contributor.authorUndurraga Fourcade, Eduardo Andrés
dc.contributor.authorGarcía, Christian
dc.contributor.authorNájera, Manuel
dc.contributor.authorBertoglia, María Paz
dc.contributor.authorVergara, Verónica
dc.contributor.authorFernández, Jorge
dc.contributor.authorGarcía-Escorza, Heriberto
dc.contributor.authorAraos, Rafael
dc.date.accessioned2023-11-10T17:44:34Z
dc.date.available2023-11-10T17:44:34Z
dc.date.issued2023
dc.description.abstractIn light of the ongoing COVID-19 pandemic and the emergence of new SARSCoV-2 variants, understanding the effectiveness of various booster vaccination regimens is pivotal. In Chile, using a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluate the effectiveness against COVID-19- related intensive care unit (ICU) admissions and death of mRNA based second vaccine boosters for four different three-dose background regimes: BNT162b2 primary series followed by a homologous booster, and CoronaVac primary series followed by an mRNA booster, a homologous booster, and a ChAdOx-1 booster. We estimate the vaccine effectiveness weekly from February 14 to August 15, 2022, by determining hazard ratios of immunization over nonvaccination, accounting for relevant confounders. The overall adjusted effectiveness of a second mRNA booster shot is 88.2% (95%CI, 86.2–89.9) against ICU admissions and 90.5% (95%CI 89.4–91.4) against death. Vaccine effectiveness shows a mild decrease for all regimens and outcomes,probably linked to the introduction of BA.4 and BA.5 Omicron sub-lineages and the waning ofimmunity. Based on our findings, individuals might not need additional boosters for at least 6 months after receiving a second mRNA booster shot in this setting.
dc.fechaingreso.objetodigital2023-10-30
dc.format.extent7 páginas
dc.fuente.origenSIPA
dc.identifier.doi10.1038/s41467-023-41942-y
dc.identifier.eissn2041-1723
dc.identifier.urihttps://doi.org/10.1038/s41467-023-41942-y
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/75282
dc.identifier.wosidWOS:001088086300001
dc.information.autorucFacultad de Matemáticas; Jara Vallejos, Alejandro Antonio; 0000-0002-2282-353X; 127927
dc.information.autorucEscuela de Gobierno; Undurraga Fourcade, Eduardo Andrés; 0000-0002-4425-1253; 12868
dc.issue.numero14
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final7
dc.pagina.inicio1
dc.revistaNature Communications
dc.rightsacceso abierto
dc.subjectCovid 19
dc.subjectInmunización
dc.subjectPandemia
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEffectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile
dc.typeartículo
sipa.codpersvinculados127927
sipa.codpersvinculados12868
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s41467-023-41942-y.pdf
Size:
695.23 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas